Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terazosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | GLA | P06280 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terazosin SCHEMBL41546 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL30684952 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL5424458 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL41545 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL5427410 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL31284920 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL8057933 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL5525882 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL9053035 | 0.98 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL1133792 | 0.98 | KDM4E (0.96) | KDM4EALDH1A1HPGDGLAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 20351 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727545-A2 | COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS | Neurawell Therapeutics (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-12599554-B2 | Pharmaceutical formulations comprising tadalafil | KYDES PHARMACEUTICALS LLC (US) | 2026-04-14 | — | — | US | claimed |
| US-12569575-B2 | Radiopaque particle compositions and uses thereof | GUSTAVE ROUSSY TRANSFERT (FR) | 2026-03-10 | — | — | US | claimed |
| US-20250375376-A1 | STABLE ORAL LIQUID COMPOSITION OF TERAZOSIN | Novitium Pharma LLC (US) | 2025-12-11 | — | — | US | claimed |
| US-20250367321-A1 | COMPOSITIONS AND METHODS INVOLVING ADGRG6 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-04 | — | — | US | claimed |
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | claimed |
| US-20250319068-A1 | TREATMENT OF DISEASES VIA ADMINISTRATION OF BUNTANETAP AND AN ANTIHYPERTENSIVE AGENT | ANNOVIS BIO, INC. (US) | 2025-10-16 | — | — | US | claimed |
| US-20250302887-A1 | AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE | AOBIOME LLC (US) | 2025-10-02 | — | — | US | claimed |
| US-12427108-B2 | Stable oral liquid composition of terazosin | Novitium Pharma LLC (US) | 2025-09-30 | — | — | US | claimed |
| EP-0526001-A1 | Substituted triazolinones | MERCK & CO. INC. (US) | 1993-02-03 | — | — | EP | claimed |
| WO-1993001177-A1 | SUBSTITUTED TRIAZOLINONES | MERCK & CO., INC. (US) | 1993-01-21 | — | — | WO | claimed |
| WO-1992016213-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | claimed |
| WO-1992014453-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| WO-1992011851-A1 | METHOD AND COMPOSITIONS FOR TREATMENT OF SEXUAL IMPOTENCE | LARAGH JOHN H (US) | 1992-07-23 | — | — | WO | claimed |
| WO-1992000073-A1 | R(+)-TERAZOSIN | ABBOTT LABORATORIES (US) | 1992-01-09 | — | — | WO | claimed |
| EP-0430287-A2 | Sustained-release drug dosage units | ABBOTT LABORATORIES (US) | 1991-06-05 | — | — | EP | claimed |
| EP-0189336-A1 | Pharmaceutical compositions containing an alpha-blocker and a calcium antagonist | SYNTHELABO (FR) | 1986-07-30 | — | — | EP | claimed |
| US-4112097-A | QUINAZOLINES | ABBOTT LABORATORIES (US) | 1978-09-05 | — | — | US | claimed |
| US-4026894-A | 2(4(TETRAHYDRO-2-FUROYL)-PIPERAZINO)-4-AMINO-6,7-DIMETHOXYQUINAZOLINE OR 2-(4(TETRAHYDROPYRAN-2-CARBONYL)-PIPERAZINYL)-4-AMINO-6,7 -DIMETHOXYQUINAZOLINE | ABBOTT LABORATORIES (US) | 1977-05-31 | — | — | US | claimed |